Angelman syndrome in two siblings: clinical case

Background. Angelman syndrome (AS) is rare genetic disease characterized by severe mental retardation, gross developmental speech delay, facial dysmorphia, disorders of motor activity, behavior and sleep, epileptic seizures manifestation. Pathology refers to diseases of genomic imprinting. There are four possible mechanisms of pathology development in Angelman syndrome: 15q11.2-q13 deletion on the chromosome 15 of maternal origin, mutation of the ubiquitin ligase (UBE3A) gene at the 15q11.2 locus on the chromosome 15 of maternal origin, uniparental disomy of the 15q11.2-q13 region of paternal origin, imprinting center defect.

Clinical case description. Clinical picture of Angelman syndrome in two twin sibs (boy E., girl V.) observed in Children’s City Clinical Hospital № 1 in Nizhny Novgorod is presented. Children from consecutive pregnancy with dichorionic-diamniotic twins; preterm birth at 30 weeks. There was burdened obstetric-biological and perinatal history due to the threatened miscarriage during this pregnancy and due to asphyxia of both children during delivery. The disease has classical course in both patients: static functions development delay, gross developmental speech and intellectual delay, behavioral and motor disorders (stereotypy, tremor, ataxia, episodes of unmotivated laughter, sleep disorders), presence of typical facial dysmorphia. This diagnosis was confirmed by the molecular genetic study (boy — mutation in exon 7 of the UBE3A gene, girl — mutations in exons 6 and 7 of the UBE3A gene). Features of epileptic seizure therapy in both patients are presented.

Conclusion. The presented clinical case demonstrates typical clinical picture of AS in two sibs confirmed by molecular genetic study. The therapy of this syndrome is very complicated. The described patients require constant anticonvulsant therapy, observation of neurologist, psychotherapist, working with speech pathologist. Complete correction of this syndrome is impossible. 

1. Angelman H. ‘Puppet’ Children: A report of three cases. Dev Med Child Neurol. 1965;7(6):681–688. doi: https://doi.org/10.1111/j.1469-8749.1965.tb07844.x

2. Hart H. ‘Puppet’ children. A report on three cases (1965). Dev Med Child Neurol. 2008;50(8):564. doi: https://doi.org/10.1111/j.1469-8749.2008.03035.x

3. Gorchkhanova ZK, Nikolaeva EA, Bochenkov SV, Belousova ED. Clinical manifestations of Angelman syndrome in children. Rossiyskiy Vestnik Perinatologii i Pediatrii = Russian Bulletin of Perinatology and Pediatrics. 2021;66(6):63–70. (In Russ). doi: https://doi.org/10.21508/1027-4065-2021-66-6-63-70

4. Mutovin GR. Klinicheskaya genetika. Genomika i proteomika nasledstvennoi patologii: Tutorial. 3rd ed., rev. and add. Moscow: GEOTAR-Media; 2010. 832 p. (In Russ).

5. N’yusbaum RL, Mak-Ines RR, Villard KhF. Meditsinskaya genetika: Textbook. Latypova ASh, transl. from Eng.; Bochkov NP, ed. Moscow: GEOTAR-Media; 2010. 624 p. (In Russ).

6. Pearson E, Wilde L, Heald M, et al. Communication in Angelman syndrome: a scoping review. Dev Med Child Neurol. 2019;61(11):1266– 1274. doi: https://doi.org/10.1111/dmcn.14257

7. Elgersma Y, Sonzogn M. UBE3A reinstatement as a diseasemodifying therapy for Angelman syndrome. Dev Med Child Neurol. 2021;63(7):802–807. doi: https://doi.org/10.1111/dmcn.14831

8. Voropanova EB, Bobylova MYu, Mironov MB, Kulikov AV. Acute ataxia, taking place after acute respiratory viral infection in 2 y. o. girl, as a debut neurologic sign of the Angelman syndrome. Russian Journal of Child Neurology. 2015;10(1):64-70. (In Russ). doi: https://doi.org/10.17650/2073-8803-2015-1-64-70

9. Yang L, Shu X, Mao S, et al. Genotype-Phenotype Correlations in Angelman Syndrome. Genes (Basel). 2021;12(7):987. doi: https://doi.org/10.3390/genes12070987

10. Aygun D, Bjornsson HT. Clinical epigenetics: a primer for the practitioner. Dev Med Child Neurol. 2020;62(2):192–200. doi: https://doi.org/10.1111/dmcn.14398

11. Psyanchin AA, Bobylova MYu, Yakupov TZ. Sleep disorder in Angelman syndrome: causes, mechanisms and methods of correction. Literature review. Russian Journal of Child Neurology. 2022;17(3):55–62. (In Russ). doi: https://doi.org/10.17650/2073-8803-2022-17-3-55-62

12. Kuzmich GV, Bobylova MYu, Mukhin KYu, et al. EEG findings in patients with angelman syndrome. Notched slow waves and agespecific characteristics of the main EEG patterns. Russian Journal of Child Neurology. 2021;16(1-2):42–57. (In Russ). doi: https://doi.org/10.17650/2073-8803-2021-16-1-2-42-57

13. Williams CA, Angelman H, Clayton-Smith J, et al. Angelman syndrome: consensus for diagnostic criteria. Angelman Syndrome Foundation. Am J Med Genet. 1995;56(2):237–8. doi: https://doi.org/10.1002/ajmg.1320560224

14. Clayton-Smith J, Laan L. Angelman syndrome: a review of the clinical and genetic aspects. J Med Genet. 2003;40(2):87–95. doi: https://doi.org/10.1136/jmg.40.2.87

15. Bobylova MYu, Mukhin KYu, Kuzmich GV, et al. Epilepsy in Angelman syndrome. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2022;122(7):100–105. (In Russ). doi: https://doi.org/10.17116/jnevro2022122071100

16. Milazzo C, Hoener MC, Elgersma Y. Antisense oligonucleotide treatment rescues UBE3A expression and multiple phenotypes of an Angelman syndrome mouse model. JCI Insight. 2021;6(15):e145991. doi: https://doi.org/10.1172/jci.insight.145991

17. Genome Aggregation Database (gnomAD). In: Registry of Open Data on AWS. Available online: https://registry.opendata.aws/ broad-gnomad. Accessed on February 07, 2023.

18. Ryzhkova OP, Kardymon OL, Prohorchuk EB, et al. Guidelines for the interpretation of massive parallel sequencing variants (update 2018, v2). Medical genetics. 2019;18(2):3–24. (In Russ). doi: https://doi.org/10.25557/2073-7998.2019.02.3-24

19. Geerts-Haages A, Bossuyt SNV, den Besten I, et al. A novel UBE3A sequencevariant identified in eight related individuals with neurodevelopmental delay, results in a phenotype which does not match the clinical criteria of Angelman syndrome. Mol Genet Genomic Med. 2020;8(11):e1481. doi: https://doi.org/10.1002/mgg3.1481